236 related articles for article (PubMed ID: 26779437)
1. Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma.
Gabrielson A; Miller A; Banovac F; Kim A; He AR; Unger K
Front Oncol; 2015; 5():292. PubMed ID: 26779437
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
3. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
5. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study.
Mantry PS; Mehta A; Madani B; Mejia A; Shahin I
J Gastrointest Oncol; 2017 Oct; 8(5):799-807. PubMed ID: 29184683
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment tumor volume as a prognostic factor in metastatic colorectal cancer treated with selective internal radiation to the liver using yttrium-90 resin microspheres.
Bhooshan N; Sharma NK; Badiyan S; Kaiser A; Moeslein FM; Kwok Y; Amin PP; Kudryasheva S; Chuong MD
J Gastrointest Oncol; 2016 Dec; 7(6):931-937. PubMed ID: 28078116
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
Sofocleous CT; Garcia AR; Pandit-Taskar N; Do KG; Brody LA; Petre EN; Capanu M; Longing AP; Chou JF; Carrasquillo JA; Kemeny NE
Clin Colorectal Cancer; 2014 Mar; 13(1):27-36. PubMed ID: 24370352
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center.
Shah RM; Sheikh S; Shah J; Vivian E; Mejia A; Shahin I; Mantry PS
J Gastrointest Oncol; 2021 Aug; 12(4):1718-1731. PubMed ID: 34532122
[TBL] [Abstract][Full Text] [Related]
9. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
10. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C).
Goswami P; Adeniran OR; K Frantz S; Matsuoka L; Du L; Gandhi RT; Collins ZS; Matrana MR; Petroziello M; Brower JS; Sze DY; Kennedy AS; Golzarian J; Wang EA; Brown DB
BMC Gastroenterol; 2022 Nov; 22(1):467. PubMed ID: 36396989
[TBL] [Abstract][Full Text] [Related]
11. Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry.
Wang TH; Huang PI; Hu YW; Lin KH; Liu CS; Lin YY; Liu CA; Tseng HS; Liu YM; Lee RC
PLoS One; 2018; 13(1):e0190098. PubMed ID: 29293557
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Selective Internal Radionuclide Therapy with
Bellendorf A; Mader N; Mueller SP; Ezziddin S; Bockisch A; Grafe H; Best J; Goebel J; Pöppel TD; Sabet A
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256934
[TBL] [Abstract][Full Text] [Related]
14. Correlation of radiation dose and activity with clinical outcomes in metastatic colorectal cancer after selective internal radiation therapy using yttrium-90 resin microspheres.
Badiyan S; Bhooshan N; Chuong MD; Sharma N; Akhter N; Etezadi V; Hausner P; Kudryasheva S; Kaiser A; Becker S; Guerrero M; Yi BY
Nucl Med Commun; 2018 Oct; 39(10):915-920. PubMed ID: 30124600
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90 (Y-90) resin microsphere therapy for patients with unresectable hepatocellular carcinoma. Identification of successful treatment response predictors and patient selection.
Arslan N; Ince S; Okuyucu K; San H; Alagoz E; Karadurmus N; Karaman B; Ercin CN
Ann Ital Chir; 2021; 92():623-631. PubMed ID: 35166222
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma.
Van Thai N; Thinh NT; Ky TD; Bang MH; Giang DT; Ha LN; Son MH; Tien DD; Lee HW
BMC Gastroenterol; 2021 May; 21(1):216. PubMed ID: 33980171
[TBL] [Abstract][Full Text] [Related]
17. Anatomical Quantitative Volumetric Evaluation of Liver Segments in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy: Key Parameters Influencing Untreated Liver Hypertrophy.
Girardet R; Knebel JF; Dromain C; Vietti Violi N; Tsoumakidou G; Villard N; Denys A; Halkic N; Demartines N; Kobayashi K; Digklia A; Schaefer N; Prior JO; Boughdad S; Duran R
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339337
[No Abstract] [Full Text] [Related]
18. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization for Intermediate-Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression.
Ranganathan S; Gabr A; Entezari P; Gordon AC; Riaz A; Desai K; Thornburg B; Kulik L; Kalyan A; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2023 Jun; 34(6):968-975. PubMed ID: 36791957
[TBL] [Abstract][Full Text] [Related]
20. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of
Mahvash A; Chartier S; Turco M; Habib P; Griffith S; Brown S; Kappadath SC
BMC Gastroenterol; 2022 Mar; 22(1):151. PubMed ID: 35346070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
